Insulet Corp. (NASDAQ:PODD) was down 2.8% during mid-day trading on Wednesday . The company traded as low as $42.58 and last traded at $43.01, with a volume of 267,043 shares changing hands. The stock had previously closed at $44.27.

A number of equities research analysts have recently issued reports on PODD shares. Zacks Investment Research lowered Insulet Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. Leerink Swann restated an “outperform” rating and issued a $50.00 price target (up from $40.00) on shares of Insulet Corp. in a research report on Thursday, August 4th. BTIG Research started coverage on Insulet Corp. in a research report on Tuesday, July 12th. They issued a “neutral” rating for the company. Wedbush restated an “outperform” rating and issued a $44.00 price target on shares of Insulet Corp. in a research report on Wednesday, July 20th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $41.00 price objective on shares of Insulet Corp. in a report on Wednesday, July 20th. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $41.15.

The stock’s 50 day moving average is $36.14 and its 200 day moving average is $32.07. The company’s market cap is $2.47 billion.

Insulet Corp. (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.09. During the same period last year, the business earned ($0.30) earnings per share. The business had revenue of $87.30 million for the quarter, compared to analysts’ expectations of $81.10 million. The company’s revenue for the quarter was up 44.2% on a year-over-year basis. On average, equities analysts anticipate that Insulet Corp. will post ($0.44) EPS for the current year.

In other news, Director Regina O. Sommer sold 8,019 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $30.42, for a total transaction of $243,937.98. Following the completion of the transaction, the director now directly owns 20,330 shares of the company’s stock, valued at approximately $618,438.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Other hedge funds and institutional investors have modified their holdings of the company. New York State Common Retirement Fund boosted its position in shares of Insulet Corp. by 3.2% in the fourth quarter. New York State Common Retirement Fund now owns 85,940 shares of the company’s stock worth $3,249,000 after buying an additional 2,700 shares during the period. California Public Employees Retirement System boosted its stake in Insulet Corp. by 16.8% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock valued at $3,467,000 after buying an additional 13,200 shares during the last quarter. Finally, Morgan Stanley boosted its stake in Insulet Corp. by 12.0% in the fourth quarter. Morgan Stanley now owns 766,245 shares of the company’s stock valued at $28,971,000 after buying an additional 82,302 shares during the last quarter.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.